General Information of Drug Therapeutic Target (DTT) (ID: TT5HONZ)

DTT Name Calcium channel unspecific (CaC)
Gene Name CaC
DTT Type
Successful target
[1]
UniProt ID
NOUNIPROTAC
TTD ID
T45993

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
7 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bepridil DM0RKS4 Chronic/stable angina BA40.1 Approved [2]
Clevidipine butyrate DMW4M97 Hypertension BA00-BA04 Approved [3]
Felodipine DMOSW35 Hypertension BA00-BA04 Approved [4]
Isradipine DMA5XGH Hypertension BA00-BA04 Approved [2]
Nicardipine DMCDYW7 High blood pressure BA00 Approved [5]
Nimodipine DMQ0RKZ Cerebral vasospasm BA85.Z Approved [1]
Nisoldipine DM7ISKJ Hypertension BA00-BA04 Approved [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Approved Drug(s)
11 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
DIPROTEVERINE HYDROCHLORIDE DMG8U6M Angina pectoris BA40 Phase 3 [7]
Arverapamil DML27AE Irritable bowel syndrome DD91.0 Phase 2 [8]
ATI-2042 DMWP59B Atrial fibrillation BC81.3 Phase 2 [9]
HBI-3000 DM74ZKN Heart arrhythmia BC65 Phase 2 [10]
Nexopamil DML5S71 Hypertension BA00-BA04 Phase 2 [11]
S-2150 DMTAX8B Angina pectoris BA40 Phase 2 [12]
CM2489 DMMC6YR Psoriasis vulgaris EA90 Phase 1 [13]
DSP-0565 DMY95MZ Epilepsy 8A60-8A68 Phase 1 [14]
Elpetrigine DMIV04R Bipolar disorder 6A60 Phase 1 [15]
Tetrandrine DMAOJBX Sarcoma 2A60-2C35 Phase 1 [16]
YM-16151-4 DMNLY9R Hypertension BA00-BA04 Phase 1 [17]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 Clinical Trial Drug(s)
53 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
AE-0047 DMTF9YV Hypertension BA00-BA04 Discontinued in Preregistration [18]
Monatepil maleate DM9ADLQ Angina pectoris BA40 Discontinued in Preregistration [19]
Palonidipine hydrochloride DMUH0KO Hypertension BA00-BA04 Discontinued in Preregistration [20]
Semotiadil DMYBPJ1 Hypertension BA00-BA04 Discontinued in Preregistration [21]
Anipamil DMNEM2C Hypertension BA00-BA04 Discontinued in Phase 3 [22]
ELGODIPINE HYDROCHLORIDE DMJOM31 Angina pectoris BA40 Discontinued in Phase 3 [23]
S-12968 DMPUED3 Hypertension BA00-BA04 Discontinued in Phase 3 [24]
AM336 DMF8KH7 Pain MG30-MG3Z Discontinued in Phase 2 [25]
BRL-32872A DMRKBIU Cardiac arrhythmias BC9Z Discontinued in Phase 2 [26]
CD-349 DM9P7Z2 Hypertension BA00-BA04 Discontinued in Phase 2 [27]
Dopropidil DMMC6H7 Angina pectoris BA40 Discontinued in Phase 2 [28]
FLOSATIDIL DMOCMXH Angina pectoris BA40 Discontinued in Phase 2 [29]
Levosemotiadil DMKSY2R Cardiac arrhythmias BC9Z Discontinued in Phase 2 [30]
Lifarizine DM3R8TI Nerve injury ND56.4 Discontinued in Phase 2 [31]
S-312-d DMQ2RDZ Epilepsy 8A60-8A68 Discontinued in Phase 2 [32]
TAMOLARIZINE HYDROCHLORIDE DM1L5UX Cognitive impairment 6D71 Discontinued in Phase 2 [33]
CEREBROCRAST DMK93VQ Nerve injury ND56.4 Discontinued in Phase 1 [34]
CERM-11956 DMQKRWO Angina pectoris BA40 Discontinued in Phase 1 [35]
IGANIDIPINE HYDROCHLORIDE DMP8MBW Glaucoma/ocular hypertension 9C61 Discontinued in Phase 1 [36]
KT-362 DM74BK8 Heart arrhythmia BC65 Discontinued in Phase 1 [37]
NP-252 DMT8IGE Hypertension BA00-BA04 Discontinued in Phase 1 [38]
SM-6586 DM6CLX9 Hypertension BA00-BA04 Discontinued in Phase 1 [39]
SR-33805 DM471IG Angina pectoris BA40 Discontinued in Phase 1 [40]
AHR-16303B DMJZ48W Hypertension BA00-BA04 Terminated [42]
AHR-16462B DMJ6BEO Hypertension BA00-BA04 Terminated [43]
AJ-3941 DMOJTZV Cerebrovascular ischaemia 8B1Z Terminated [44]
CD-832 DM5FEBQ Angina pectoris BA40 Terminated [45]
Clentiazem DM8TQC9 Angina pectoris BA40 Terminated [46]
Darodipine DM160FM Cerebrovascular ischaemia 8B1Z Terminated [47]
DHP-218 DM5VFR0 Hypertension BA00-BA04 Terminated [48]
E-2050 DMQKEHA Cerebrovascular ischaemia 8B1Z Terminated [49]
Emopamil DMW210B Cerebrovascular ischaemia 8B1Z Terminated [50]
LAS-30538 DM07S4N Hyperinsulinemia 5A4Y Terminated [51]
Naltiazem hydrochloride DM7T2FO Angina pectoris BA40 Terminated [52]
NNC-09-0026 DMGEHZ9 Cerebrovascular ischaemia 8B1Z Terminated [53]
NS-638 DMPT74G Cerebrovascular ischaemia 8B1Z Terminated [54]
NS-649 DMXKMRV Alzheimer disease 8A20 Terminated [55]
NS-696 DMI46T3 Epilepsy 8A60-8A68 Terminated [56]
Pranidipine DMI2N9H Angina pectoris BA40 Terminated [57]
RS-93522 DMZHS9U Hypertension BA00-BA04 Terminated [58]
RWJ-22108 DMBXDQG Allergy 4A80-4A85 Terminated [59]
RWJ-37868 DM17WNG Epilepsy 8A60-8A68 Terminated [60]
SB-206284A DM5ZPQJ Cerebrovascular ischaemia 8B1Z Terminated [61]
SB-237376 DMBCANZ Arrhythmia BC9Z Terminated [62]
SDZ-249482 DMPZLKC Pain MG30-MG3Z Terminated [63]
SIM-6080 DMBZ7SF Angina pectoris BA40 Terminated [64]
Siratiazem DMG90YW Angina pectoris BA40 Terminated [65]
SKF-96365 DMI79JN Angina pectoris BA40 Terminated [66]
SQ-33351 DM083JB Hypertension BA00-BA04 Terminated [67]
UK-51656 DM23YPS Cardiovascular disease BA00-BE2Z Terminated [68]
VUF-8929 DM0CWJZ Heart failure BD10-BD13 Terminated [69]
Z-6568 DMQ6K8J Hypertension BA00-BA04 Terminated [70]
ZM-224832 DM8V0YA Hypertension BA00-BA04 Terminated [71]
------------------------------------------------------------------------------------
⏷ Show the Full List of 53 Discontinued Drug(s)
1 Preclinical Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Rycals DMXM2BZ Heart failure BD10-BD13 Preclinical [41]
------------------------------------------------------------------------------------
6 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
AGN-190744 DMIKDAR Discovery agent N.A. Investigative [72]
BELFOSDIL DM0WOS6 Discovery agent N.A. Investigative [73]
CD-832.HCL DMFYWE3 Discovery agent N.A. Investigative [74]
leualacin DMV40XH Discovery agent N.A. Investigative [75]
SR-33805A DMPO4WX Hypertension BA00-BA04 Investigative [76]
TELUDIPINE HYDROCHLORIDE DMT4NWX Hypertension BA00-BA04 Investigative [77]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Investigative Drug(s)

References

1 Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
4 Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7.
5 Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20.
6 RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12.
7 Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9.
8 BJMP 2010;3(4):a342
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.
11 Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
12 Pharmacodynamics of S-2150, a simultaneous calcium-blocking and alpha1-inhibiting antihypertensive drug, in rats. J Pharm Pharmacol. 2000 Mar;52(3):273-80.
13 Molecular pharmacology of store-operated CRAC channels
14 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035668)
15 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
16 Tetrandrine: a novel calcium channel antagonist inhibits type I calcium channels in neuroblastoma cells. Neuropharmacology. 1991 Dec;30(12A):1325-31.
17 Antianginal effects of YM-16151-4 in various experimental angina models. J Cardiovasc Pharmacol. 1993 May;21(5):701-8.
18 AE0047-mediated calcium channel blocking in vascular smooth muscles. Gen Pharmacol. 1997 Sep;29(3):337-43.
19 Antihypertensive, antiatherosclerotic, and plasma lipid-lowering effects of monatepil, a novel calcium antagonist with alpha 1-adrenoceptor-blocking activity in experimental animals. Am J Hypertens. 1994 Oct;7(10 Pt 2):131S-40S.
20 Effect of palonidipine hydrochloride (TC-81), a novel calcium antagonist, on the canine coronary artery. Nihon Yakurigaku Zasshi. 1993 Jul;102(1):23-33.
21 Thyroid hypertrophic effect of semotiadil fumarate, a new calcium antagonist, in rats. J Toxicol Sci. 2000 May;25(2):121-30.
22 Effects of the novel calcium channel blocker, anipamil, on the isolated rabbit heart. Comparison with verapamil and gallopamil. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):339-44.
23 The calcium channel blocker amlodipine exerts its anti-proliferative action via p21(Waf1/Cip1) gene activation. FASEB J. 2004 Oct;18(13):1516-23.
24 (+)-S-12967 and (-)-S-12968: 1,4-dihydropyridine stereoisomers with calcium channel agonistic and antagonistic properties in rat resistance arteries. Br J Pharmacol. 1991 Jul;103(3):1703-8.
25 Intravenous injection of leconotide, an omega conotoxin: synergistic antihyperalgesic effects with morphine in a rat model of bone cancer pain.Pain Med.2011 Jun;12(6):923-41.
26 Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile... J Pharmacol Exp Ther. 1996 Feb;276(2):637-46.
27 A new Ca-antagonist, CD-349, binding to the Ca-channel of rat myocardium and brain and hog coronary artery. Jpn J Pharmacol. 1988 Dec;48(4):453-62.
28 Effects of bepridil and CERM 4205 (ORG 30701) on the relation between cardiac cycle length and QT duration in healthy volunteers. Am J Cardiol. 1990 Sep 1;66(5):636-41.
29 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
30 Binding study of semotiadil and levosemotiadil with alpha(1)-acid glycoprotein using high-performance frontal analysis. Anal Biochem. 1999 Oct 1;274(1):27-33.
31 The effect of lifarizine (RS-87476), a novel sodium and calcium channel modulator, on ischaemic dopamine depletion in the corpus striatum of the gerbil. Br J Pharmacol. 1993 May;109(1):175-7.
32 Protective effects of a selective L-type voltage-sensitive calcium channel blocker, S-312-d, on neuronal cell death. Biochem Pharmacol. 2004 Mar 15;67(6):1153-65.
33 Reversal of multidrug resistance in human leukemia K562 by tamolarizine, a novel calcium antagonist. Jpn J Pharmacol. 2000 Mar;82(3):265-8.
34 The dihydropyridine analogue cerebrocrast blocks both T-type and L-type calcium currents. Can J Physiol Pharmacol. 2009 Nov;87(11):923-32.
35 The anti-ischaemic activity of the novel compound, CERM 11956, compared with that of bepridil and nifedipine in isolated guinea-pig hearts. Eur J Pharmacol. 1988 May 10;149(3):195-203.
36 Improving effects of topical administration of iganidipine, a new calcium channel blocker, on the impaired visual evoked potential after endothelin-1 injection into the vitreous body of rabbits. CurrEye Res. 2000 Feb;20(2):101-8.
37 Comparative cardiac effects of KT-362 and verapamil in isolated heart--correlation to calcium channel current depression. J Cardiovasc Pharmacol. 1991 Oct;18(4):594-604.
38 Pharmacological characteristics of NP-252, a new dihydropyridine slow Ca2+ channel blocker, in isolated rabbit vascular smooth muscle and guinea pig myocardium: vascular selectivity. Eur J Pharmacol.1991 Oct 22;203(3):337-44.
39 Calcium channel blocking properties of SM-6586 in rat heart and brain as assessed by radioligand binding assay. Jpn J Pharmacol. 1993 Oct;63(2):165-9.
40 Effects of a new class of calcium antagonists, SR33557 (fantofarone) and SR33805, on neuronal voltage-activated Ca++ channels. J Pharmacol Exp Ther. 1994 Dec;271(3):1348-52.
41 Fixing ryanodine receptor Ca2+ leak - a novel therapeutic strategy for contractile failure in heart and skeletal muscle. Drug Discov Today Dis Mech. 2010 SUMMER; 7(2): e151-e157.
42 AHR-16303B, a novel antagonist of 5-HT2 receptors and voltage-sensitive calcium channels. J Cardiovasc Pharmacol. 1991 Jan;17(1):41-53.
43 A pharmacological and biochemical examination of AHR-16462B, a novel calcium antagonist coronary vasodilator/antihypertensive. Drug Development Research. 01/1991; 22(3):259-271.
44 Prevention by the new Ca2+ channel antagonist, AJ-3941, of loss of endothelium-dependent relaxation after subarachnoid hemorrhage in rats. Eur J Pharmacol. 1996 Nov 21;315(3):297-303.
45 Effects of CD-832, a new calcium antagonist, on intracranial pressure in anesthetized dogs. Life Sci. 1998;62(19):PL283-8.
46 Coronary and cardiac sensitivity to the vasoselective benzothiazepine-like calcium antagonist, clentiazem, in experimental heart failure. Cardiovasc Drugs Ther. 1997 Mar;11(1):71-9.
47 Effect of cromakalim on contractions in rabbit isolated renal artery in the presence and absence of extracellular Ca2+. Br J Pharmacol. 1989 Dec;98(4):1303-11.
48 Effect of DHP-218, a novel dihydropyridine phosphonate, on atrioventricular nodal conductivity compared with its vascular effect in dogs. J Cardiovasc Pharmacol. 1987 Sep;10(3):274-9.
49 Solubility of E2050 at various pH: a case in which apparent solubility is affected by the amount of excess solid. J Pharm Sci. 2002 Jun;91(6):1445-55.
50 Calcium entry and 5-HT2 receptor blockade in oliguric ischaemic acute renal failure: effects of levemopamil in conscious rats. Br J Pharmacol. 1996 Mar;117(6):1348-54.
51 The calcium channel blocker LAS 30538, unlike nifedipine, verapamil, diltiazem or flunarizine, potently inhibits insulin secretion in-vivo in rats and dogs. J Pharm Pharmacol. 1992 Oct;44(10):851-5.
52 Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil. Crit Care Med. 2007 Sep;35(9):2071-5.
53 Pharmacological profile of a novel neuronal calcium channel blocker includes reduced cerebral damage and neurological deficits in rat focal ischemia. Pharmacol Biochem Behav. 1994 May;48(1):77-85.
54 Pharmacological profile and anti-ischemic properties of the Ca(2+)-channel blocker NS-638. Neurol Res. 1995 Oct;17(5):353-60.
55 Effects of Ca2+ and Na+ channel inhibitors in vitro and in global cerebral ischaemia in vivo. Eur J Pharmacol. 1997 Aug 6;332(2):121-31.
56 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005355)
57 Pranidipine, a new 1,4-dihydropyridine calcium channel blocker, enhances cyclic GMP-independent nitric oxide-induced relaxation of the rat aorta. Mol Cell Biochem. 1998 Jan;178(1-2):335-43.
58 Intranasal delivery of RS-93522, a dihydropyridine-type calcium-channel antagonist. Pharm Res. 1991 Jan;8(1):134-5.
59 Design and discovery of RWJ 22108--a novel bronchoselective calcium channel blocker. Drug Des Discov. 1998 May;15(3):135-48.
60 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008896)
61 The effects of SB 206284A, a novel neuronal calcium-channel antagonist, in models of cerebral ischemia. J Cereb Blood Flow Metab. 1997 Apr;17(4):421-9.
62 Electrophysiologic effects of SB-237376: a new antiarrhythmic compound with dual potassium and calcium channel blocking action. J Cardiovasc Pharmacol. 2003 Mar;41(3):414-21.
63 Physiology and Pharmacology of the Vanilloid Receptor. Curr Neuropharmacol. 2006 January; 4(1): 1-15.
64 Determination of the calcium antagonist SIM6080 and its N- and O-demethylated metabolites in plasma, urine and tissues by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996 Feb 9;676(1):77-85.
65 Comparison of the effects of diltiazem and its analogue siratiazem on contractility in arteries, ileum and cardiac muscle. J Auton Pharmacol. 1995 Apr;15(2):107-13.
66 The transient receptor potential channel antagonist SKF96365 is a potent blocker of low-voltage-activated T-type calcium channels. Br J Pharmacol. 2010 Jul;160(6):1464-75.
67 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002577)
68 Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists. J Med Chem. 1990 Feb;33(2):585-91.
69 In vitro and in vivo characterization of a calcium modulator of the diphenylalkylamine type with selective coronary dilatory properties. Arzneimittelforschung. 1997 Nov;47(11):1211-8.
70 Determination of the dihydropyridine aryloxypropanolamine Z6568 and its acidic metabolites in plasma, urine and tissues by solid phase extraction and liquid chromatography/negative-ion mass spectrometry. J Mass Spectrom. 1996 Sep;31(9):994-1002.
71 Diuretic and antihypertensive activity of ZENECA ZM224,832: a novel eukalemic diuretic with calcium channel blocking activity. Pharmacology. 1994 Mar;48(3):167-75.
72 The antiinflammatory activity of topically applied novel calcium-channel antagonists. Inflammation. 1995 Apr;19(2):261-75.
73 Determination of belfosdil, a new calcium channel blocker, in human plasma by capillary gas chromatography with nitrogen-phosphorus detection. J Chromatogr. 1990 May 18;527(2):343-50.
74 Actions of a new Ca2+ channel antagonist, CD832, on two types of Ca2+ channels in smooth muscle. Eur J Pharmacol. 1994 Feb 11;252(3):267-74.
75 Leualacin, a novel calcium blocker from Hapsidospora irregularis. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties. J Antibiot (Tokyo). 1992 Jun;45(6):899-905.
76 Vascular calcium overload produced by vitamin D3, in rats. Effect of treatment with SR 33805, a novel calcium entry blocker. Cardiovasc Res. 1995 Dec;30(6):1038-43.
77 Effects of R-enantiomer (GR66234A) and L-enantiomer (GR66235A) of telupidine, a new dihydropyridine derivative, on cell lines displaying the multidrug resistant phenotype. Haematologica. 1994 Jul-Aug;79(4):328-33.